Jaguar health licenses fda-approved oral mucositis product for u.s. market, initiating commercial footprint in its core focus area of cancer supportive care

Jaguar planning to begin commercial launch in q3 2024 for gelclair®, the company's third prescription product oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a national comprehensive cancer network task force san francisco, ca / accesswire / april 16, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that it has signed an exclusive 5-year in-license agreement with united kingdom-based venture life group plc ("venture life"), an international consumer health company focused on the global self-care market, for venture life's fda-approved oral mucositis prescription product, gelclair, for the u.s. market. "we are very happy to have executed the in-license agreement for gelclair - and thus to have initiated jaguar's commercial footprint in our core focus area of cancer supportive care," said lisa conte, jaguar's president and ceo.
JAGX Ratings Summary
JAGX Quant Ranking